ADCT · ADC Therapeutics SA
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $79.58M | $81.36M | $70.84M | $69.56M | $209.91M | $33.92M | $0 | $2.34M | $1.14M | |
| — | $5.8M | $5.95M | $2.53M | $3.3M | $1.39M | $0 | $0 | — | |
| — | $75.56M | $64.89M | $67.03M | $206.61M | $32.52M | $0 | $2.34M | — | |
| — | 92.87% | 91.6% | 96.36% | 98.43% | 95.89% | — | 100% | — | |
| $82.23M | $104.01M | $109.63M | $127.13M | $186.46M | $158M | $142.03M | $107.54M | $118.31M | |
| $47.95M | $43.37M | $44.02M | $57.46M | $69.05M | $64.78M | $22.1M | $0 | $0 | |
| $37.38M | $36.56M | $41.89M | $48.42M | $74.44M | $71.46M | $55.13M | $14.2M | $8.77M | |
| $1.08M | — | — | — | $1.02M | $920K | $774K | $552K | $488K | |
| $179.13M | $202.86M | $201.49M | $235.54M | $333.25M | — | — | — | — | |
| -$99.55M | -$121.5M | -$130.65M | -$165.99M | -$123.34M | -$261.72M | -$219.26M | -$119.4M | -$125.94M | |
| — | -149.34% | -184.44% | -238.63% | -58.76% | -771.65% | — | -5102.52% | -11047.46% | |
| -$135.38M | — | — | — | -$122.33M | -$260.8M | -$218.49M | -$118.85M | -$125.45M | |
| $52.26M | $51.63M | $50.21M | $46.33M | $36.73M | $18.34M | $4.93M | $156K | $0 | |
| $8.64M | $8.81M | $12.27M | $10.54M | $2.57M | — | — | — | — | |
| $2.24M | -$20.11M | -$25.48M | -$29.43M | -$23.47M | — | — | — | — | |
| — | $0 | -$1.54M | -$5.53M | -$10.08M | — | — | — | — | |
| -$97.31M | -$141.61M | -$156.14M | -$195.42M | -$146.82M | -$251.51M | -$245.96M | -$115.9M | -$122.87M | |
| -$404K | $1.02M | $166K | $39.11M | $227K | -$21.48M | $327K | $582K | $224K | |
| -$96.89M | -$142.62M | -$157.85M | -$240.05M | -$157.13M | -$230.03M | -$246.29M | -$116.48M | -$123.1M | |
| — | -175.31% | -222.83% | -345.11% | -74.86% | -678.2% | — | -4977.95% | -10797.89% | |
| -$97.33M | -$141.72M | -$159.18M | -$241.97M | -$153.55M | — | — | — | — | |
| USD/shares | -$0.58 | -$1.12 | -$1.62 | -$2.94 | -$2.01 | — | — | — | — |
| USD/shares | -$0.58 | -$1.12 | -$1.62 | -$2.94 | -$2.01 | — | — | — | — |
| shares | — | 127.07M | 97.16M | 81.71M | 78.15M | — | — | — | — |
| shares | — | 127.07M | 97.16M | 81.71M | 78.15M | — | — | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2021: $141K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 46 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $81,357,000 | $70,837,000 | $69,558,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United States | $73,551,000 | $69,280,000 | $69,060,000 | $74,908,000 |
| EMEA | $7,806,000 | $1,557,000 | $498,000 | $105,000,000 |
| Japan | — | — | — | $30,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $73,551,000 | $69,280,000 | $69,060,000 | $74,908,000 | — | — | — |
| License and Royalty Revenue | $7,806,000 | $1,557,000 | — | — | — | — | — |
| License Revenues | $5,000,000 | $0 | — | $135,000,000 | — | — | — |
| Royalty Revenue | $2,806,000 | $1,557,000 | $498,000 | $0 | — | — | — |
| Contract Revenue | — | — | — | — | $0 | $0 | $2,340,000 |
| Product Revenue | — | — | — | — | $33,917,000 | $0 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$121,499,000 | -$130,654,000 | -$165,986,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -149.3% | -184.4% | -238.6% |